TABLE IV.
Dose changes in target regions, using superficial parotid lobe–sparing technology
| Variable |
Plan
|
p Value | |
|---|---|---|---|
| Control | Test | ||
| ptvnx V110 (%) | |||
| Mean | 1.65±2.61 | 3.39±5.33 | 0.10 |
| Range | 0.00 to 8.78 | 0.00 to 22.83 | |
| ptvnx V100 (%) | |||
| Mean | 99.62±0.66 | 99.73±0.57 | 0.06 |
| Range | 97.80 to 100.00 | 97.89 to 100.00 | |
| ptvnx V95 (%) | |||
| Mean | 99.94±0.19 | 99.92±0.29 | 0.58 |
| Range | 99.21 to 100.00 | 99.10 to 100.00 | |
| V60 (%) | |||
| Mean | 99.91±0.20 | 99.86±0.39 | 0.64 |
| Range | 99.08 to 100.00 | 97.97 to 100.00 | |
| V54 (%) | |||
| Mean | 99.40±0.55 | 99.32±0.47 | 0.30 |
| Range | 97.88 to 99.97 | 98.34 to 99.95 | |
| Dmax | |||
| Mean | 77.95±1.88 | 78.84±2.56 | 0.07 |
| Range | 74.24 to 85.52 | 74.39 to 85.17 | |
| Dmean to ptvnx | |||
| Mean | 73.19±0.94 | 73.83±2.02 | 0.04 |
| Range | 70.87 to 74.81 | 71.32 to 78.25 | |
| Dmean to ptv1 | |||
| Mean | 69.77±1.57 | 70.15±1.67 | 0.01 |
| Range | 65.48 to 72.72 | 64.80 to 72.73 | |
| Dmean to ptv2 | |||
| Mean | 62.10±1.05 | 63.06±1.74 | 0.03 |
| Range | 59.80 to 64.91 | 60.15 to 69.90 | |
| Homogeneity index | |||
| Mean | 1.12±0.02 | 1.13±0.03 | 0.07 |
| Range | 1.09 to 1.18 | 1.09 to 1.22 | |
| Conformity index | |||
| Mean | 1.00±0.01 | 1.00±0.01 | 0.06 |
| Range | 0.98 to 1.00 | 0.98 to 1.00 | |
ptvnx, ptv1, ptv2 = planning target volume for the tumour, for the high-risk region, and for the potentially involved region; V110, V100, V95 = volume covered by more than 110%, 100%, or 95% of the prescribed dose; V60, V54 = percentage of the volume receiving 60 Gy or more, or 54 Gy or more; Dmax = maximum dose in target regions; Dmean = mean dose.